Background Pulmonary hypertension (PH) is a common disorder in patients with idiopathic
pulmonary fibrosis (IPF) and portends a poor prognosis. Recent studies using vasodilators …

Background Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal
fibrotic disorder, with no curative therapies. The signal transducer and activator of …

Objectives Hypoxia is an important risk factor for pulmonary arterial remodelling in
pulmonary arterial hypertension (PAH), and the Janus kinase 2 (JAK2) is believed to be …

Idiopathic pulmonary fibrosis (IPF) and rheumatoid arthritis‐associated interstitial lung
disease (RA‐ILD) are two fibrotic interstitial lung diseases that share the usual interstitial …

In pulmonary arterial hypertension (PAH), progressive structural remodeling accounts for the
pulmonary vasculopathy including the obliteration of the lung vasculature that causes an …

Interstitial lung disease (ILD) refers to a heterogeneous group of diseases characterized by
lung fibroblast proliferation, interstitial inflammation, and fibrosis-induced lung damage. The …

Pulmonary hypertension is defined as a group of diseases characterized by a progressive
increase in pulmonary vascular resistance (PVR), which leads to right ventricular failure and …

Pulmonary hypertension (PH) is present in an important proportion of patients with interstitial
lung diseases (ILDs), encompassing a large, heterogeneous group of diffuse parenchymal …

Interstitial lung diseases (ILDs) comprise different fibrotic lung disorders characterized by
cellular proliferation, interstitial inflammation, and fibrosis. The JAK/STAT molecular pathway …

Idiopathic pulmonary fibrosis (IPF) is a fatal lung disease where the additional presence of
pulmonary hypertension (PH) reduces survival. In particular, the presence of coexistent …